Hasil Pencarian - Ursula A. Matulonis

Perbaiki Hasil
  1. 1
    Current status and evolution of preclinical drug development models of epithelial ovarian cancer

    Current status and evolution of preclinical drug development models of epithelial ovarian cancer oleh Panagiotis A Konstantinopoulos, Ursula A Matulonis

    Diterbitkan 2013-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure

    POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure oleh Elizabeth K. Lee, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers oleh Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks oleh Kun-Hsing Yu, Vincent Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Open-Source, Step-Counting Algorithm for Smartphone Data Collected in Clinical and Nonclinical Settings: Algorithm Development and Validation Study

    Open-Source, Step-Counting Algorithm for Smartphone Data Collected in Clinical and Nonclinical Settings: Algorithm Development and Validation Study oleh Marcin Straczkiewicz, Nancy L Keating, Embree Thompson, Ursula A Matulonis, Susana M Campos, Alexi A Wright, Jukka-Pekka Onnela

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

    High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. oleh Ursula A Matulonis, Michelle Hirsch, Emanuele Palescandolo, Eejung Kim, Joyce Liu, Paul van Hummelen, Laura MacConaill, Ronny Drapkin, William C Hahn

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

    Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer oleh Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu

    Diterbitkan 2019-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

    Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression oleh Brooke E. Howitt, Kyle C. Strickland, Lynette M. Sholl, Scott Rodig, Lauren L. Ritterhouse, Dipanjan Chowdhury, Alan D. D'Andrea, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Diterbitkan 2017-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

    Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal... oleh Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.

    BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. oleh Ayaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, Patricia Greninger, Ryan J March, Regina K Egan, Hoang Son Luu, Daniel G Stover, Ursula A Matulonis, Cyril H Benes, Junying Yuan

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

    Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. oleh Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart, Zhigang C Wang

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

    Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer oleh Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

    Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. oleh Stefan Bentink, Benjamin Haibe-Kains, Thomas Risch, Jian-Bing Fan, Michelle S Hirsch, Kristina Holton, Renee Rubio, Craig April, Jing Chen, Eliza Wickham-Garcia, Joyce Liu, Aedin Culhane, Ronny Drapkin, John Quackenbush, Ursula A Matulonis

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

    PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer oleh Liya Ding, Hye-Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E. Ohlson, Ben B. Li, Shaozhen Xie, Joyce F. Liu, Elizabeth H. Stover, Brooke E. Howitt, Roderick T. Bronson, Suzan Lazo, Thomas M. Roberts, Gordon J. Freeman, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Jean J. Zhao

    Diterbitkan 2018-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

    STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer oleh Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar K. Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye-Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah A. Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

    A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma oleh Elizabeth H. Stover, Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, Russell R. Broaddus, Vicky Makker, Ronny Drapkin, Joyce F. Liu, Neil S. Horowitz, Funda Meric-Bernstam, Carol Aghajanian, Robert L. Coleman, Gordon B. Mills, Lewis C. Cantley, Ursula A. Matulonis, Shannon N. Westin, Panagiotis A. Konstantinopoulos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

    Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 oleh Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Yanke Liang, Chunshan Quan, Jinhua Wang, Mingfeng Hao, Sangeetha Palakurthi, Shan Zhou, Qing Zeng, Paul T Kirschmeier, Khyati Meghani, Alan L Leggett, Jun Qi, Geoffrey I Shapiro, Joyce F Liu, Ursula A Matulonis, Charles Y Lin, Panagiotis A Konstantinopoulos, Nathanael S Gray

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

    A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer oleh Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

    Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer oleh Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

    Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer oleh Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: